ArticleFrontiers in pharmacology2026
Finerenone combined with guideline-directed medical therapy in patients with post-myocardial infarction heart failure: a real-world study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the short-term impact of finerenone combined with guideline-directed medical therapy (GDMT) on cardiac structure, function, and renal parameters in Chinese patients with post-myocardial infarction heart failure in a real-world setting. Methods: In this prospective observational cohort study, 67 patients received finerenone plus optimized GDMT for 3 months. Changes were assessed using echocardiography (measuring LVEF, GLS, left atrial strain and volume index), laboratory tests (NT-proBNP, serum potassium, renal function, urinary albumin-to-creatinine ratio [UACR]), and functional assessments (6-min walk test, Minnesota Living with Heart Failure Questionnaire). Results: Treatment significantly improved cardiac function and structure. LVEF increased from 49 (2)% to 53 (2)% (P < 0.001), GLS improved from 14 (1)% to 16 (1)% (P < 0.001), and left atrial reservoir strain increased from 27 (2)% to 32 (2)% (P < 0.001). Structural reverse remodeling was evidenced by reduced left ventricular end-diastolic diameter (54.85 [1.08] to 52.85 [0.96] mm, P < 0.001) and left atrial volume index (38.78 [2.69] to 36.25 [2.61] mL/m Conclusion: In this real-world cohort of 67 post-myocardial infarction heart failure patients, adding finerenone to GDMT for 3 months was associated with significant improvements in cardiac structure and function, a reduction in UACR, and better functional capacity and quality of life. Nevertheless, due to the single-arm design, these findings are exploratory and hypothesis-generating.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.